Professor of Cancer Pharmacology
Newcastle University, UK
Newcastle Cancer Centre Pharmacology Group
Development and validation of assays for the quantification of novel and established anticancer drugs and their metabolites.
Expertise in clinical pharmacology, pharmacokinetics and quantification of drug levels in clinical samples (blood, plasma, CSF, tumour material, etc).
CI on numerous completed and published clinical pharmacology trials over several years.
More information can be found on my research page, here.
Existing collaborations relevant to drug delivery
Current involvement in the SIOP Ependymoma clinical trial, involving pharmacokinetic and pharmacodynamic studies relating to the treatment of children with ependymoma. Pharmacokinetic studies are used to target trough drug levels in study patients receiving sodium valproate. (Collaborator: Prof. Richard Grundy, The University of Nottingham.)
Proposed involvement in INTREPID study, involving the analysis of etoposide levels in the CSF in patients aged 6 months - 18 years old with leptomeningeal dissemination of relapsed or refractory solid tumours. This study will investigate the feasibility and efficacy of continuous IVT etoposide over 3,7,10 and 14 days via the therapeutic monitoring of CSF samples. (Collaborator: Prof. David Walker, The University of Nottingham.)
Publications relevant to drug delivery
Barnett, S, Kong, J, Makin, G, Veal, GJ. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom. Br J Clin Pharmacol 2020 (In press)
Jackson, RK, Liebich, M, Berry, P, et al. Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia – a report from the UKALL 2011 trial. Eur J Cancer 2019 120: 75-85
Smith, SJ, Tyler, BM, Gould, T, et al. Overall survival in malignant glioma is significantly prolonged by neurosurgical delivery of etoposide and temozolomide from a thermo-responsive biodegradable paste. Clin Cancer Res 2019 25: 5094-5106
Hawley, J, Veal, GJ, Errington, J, McDonald, LG, Tweddle, DA. The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma associated spinal cord compression. Ped Blood Cancer 2019 e27825 1-3
Lee, CM, Zane, NR, Veal, G, Thakker, DR. Physiologically-based pharmacokinetic models for adults and children reveal a role of intracellular tubulin binding in vincristine disposition. CPT Pharmacometrics Syst Pharmacol 2019 8: 759-768
Veal, GJ, Amankwatia, EB, Paludetto, M-N, et al. Pharmacodynamic therapeutic drug monitoring for cancer: challenges, advances and future opportunities. Ther Drug Monit 2019 41: 142-159
Danilenko, M, Stamp, E, Stocken, DD, et al. Efficacy of targeting tropomyosin receptor kinase in cutaneous CYLD defective tumours (TRAC): A randomised placebo-controlled early phase trial with pegcantratinib. JAMA Dermatology 2018 154: 913-921
Zangarini, M, Berry, P, Sludden, J, et al. Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 (CHK1) inhibitor SRA737 in human plasma. Bioanalysis 2017 9: 1001-1010.
Zangarini, M, Rajan, N, Danilenko, M, Berry, P, Traversa, S, Veal, GJ. Development and validation of LC-MS/MS with in-source CID for the quantification of pegcantratinib in human skin tumours. Bioanalysis 2017 9: 279-288.
Walsh, C, Bonner, JJ, Johnson, TN, et al. Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer. Br J Clin Pharmacol 2016 81: 989-998.
Veal, GJ, Errington, J, Sastry, J, et al. Adaptive dosing of anticancer drugs in neonates – facilitating evidence-based dosing regimens. Cancer Chemother Pharmacol 2016 77: 685-692.
Veal, GJ, Errington, J, Hayden, J, et al. Carboplatin therapeutic monitoring in preterm and full-term neonates. Eur J Cancer 2015 51: 2022-2030.
Bardin, C, Veal, G, Paci, A, et al. Therapeutic drug monitoring in cancer – Are we missing a trick? Eur J Cancer 2014 50: 2005-2009.
Veal, GJ, Errington, J, Rowbotham, SE, et al. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin Cancer Res 2013 19: 469-479.
Email for contact details